- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01884974
A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases. (PH-MPD1)
A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases, and Correlation Between Patients Epidemiologic and Clinical Status and the Development of Pulmonary Hypertension.
Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates.
The purpose of this research:
- Assess Prevalence of PH in patients with CMPD in Northern Israel
- Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
study will include the following:
- sex
- age
- BMI
- ethnicity
- age diagnosed with Myeloproliferative disease
- clinical manifestations of the myeloproliferative disease
- JAK2 mutation
- known hematological complications
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Shoshan Perek, MD
- Phone Number: 972-4-8250517
- Email: shoshanpe@clalit.org.il
Study Locations
-
-
-
Haifa, Israel, 34632
- Recruiting
- Pulmonology Institute, Carmel Medical Center
-
Contact:
- Shoshan Perek, MD
- Phone Number: 972-4-8250517
-
Principal Investigator:
- Shoshan Perek, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
1) consenting patients diagnosed with a myeloproliferative disease
Exclusion Criteria:
1) Refusal to have an echocardiogram or answer the St. George respiratory questionnaire
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
myeloproliferative disease
Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
|
Echocardiogram, demographic data, St George respiratory questioner
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pulmonary hypertension
Time Frame: 1 year
|
all patients with myeloproliferative diseases in the study will be evaluated by an echocardiogram.
Pulmonary hypertension will be considered when the average pulmonary arterial pressure is equal or above 25 mmHg.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
St George Respiratory Questionnaire
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shoshan Perek, MD, Carmel Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMC-12-0060-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
BayerCompletedPrimary HypertensionChina
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
National Taiwan University HospitalUnknownPulmonary HypertensionTaiwan
Clinical Trials on myeloproliferative disease
-
Institut Paoli-CalmettesNot yet recruiting
-
Assiut UniversityRecruiting
-
University Hospital, AngersNot yet recruitingPrimary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative NeoplasmFrance
-
AstraZenecaClalit Health ServicesCompletedCOVID-19 | SARS-CoV-2Israel
-
Herlev and Gentofte HospitalKarolinska InstitutetCompleted
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
The University of Texas Health Science Center at...Department of Health and Human Services; Centers for Disease Control and Prevention and other collaboratorsCompleted
-
Fundació Institut de Recerca de l'Hospital de la...Active, not recruitingParkinson Disease | Huntington DiseaseSpain
-
University of AarhusCompleted
-
Assiut UniversityNot yet recruiting